1496P - Sunitinib malate in clear cell sarcoma

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Sarcoma
Presenter Silvia Stacchiotti
Authors S. Stacchiotti1, E. Palassini2, T. Negri3, C. Morosi4, A. Messina4, R. Patuzzo5, A. Gronchi6, S. Pilotti3, P.G. Casali2
  • 1Oncologia Medica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3Pathology And Molecular Biology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 4Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori,, Milan/IT
  • 5Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 6Department Of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT

Abstract

Background

Clear cell sarcoma (CCS) is a rare soft tissue sarcoma, characterized in most cases by the t(12;22), resulting in the EWS-ATFE1 fusion protein. It has a high metastatic potential. CCS is poorly sensitive to chemotherapy. We already reported on the activity of sunitinib (SM) in one case of CCS.

Methods

Since September 2009, 9 patients with progressive, metastatic CCS (M/F 3/6; median age 36 yrs; translocated/ non translocated: 6/3; site of primary: extremities 6, other 3; pretreated: 9) have been treated with continuous SM 37.5 mg/day, on a named basis. PET response was assessed in 6 cases. Responses were evaluated after 2 months from baseline, then every 3 months by CT scan and/or MRI, according to RECIST. Pre-treatment PDGFRB and VEGFR status analysis by immunohistochemistry, western/blotting and phospho-RTK array is ongoing in evaluable cases.

Results

At the time of the present analysis, 6/9 pts are evaluable for response (1 early interruption; 2 just started), and 4 patients are still on treatment. After 3 months of SM, 3 patient had a RECIST partial response (PR) (50%), along with subjective improvement in symptoms, 1 stable disease (SD), 2 progressive disease (PD). PET was consistent. One patient had a complicated major response characterized by an ulcer to the site of previous surgery; thus she underwent surgery with evidence of pathologic partial response, marked by extensive necrosis. The median PFS is 5 months (range 2-7).

Conclusions

SM is active in a proportion of CCS. Prospective studies are needed.

Disclosure

S. Stacchiotti: Pfizer: reseach grant for studies in which my Institution is involved; honoraria.

E. Palassini: Pfizer: research grant for studies in which my Institution is involved.

P.G. Casali: Pfizer: research funds for studies in which my Institution is involved; Compensated Advisory; Honoraria.

All other authors have declared no conflicts of interest.